Loading…
Underlying
Underlying Price
$6.01
Type
Put
Strike
9
Expiration
Dec 24, 2026
DTE
41d
Moneyness
ITM
Intrinsic
$2.99
IBRX 9 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.93 | +13.41% | 2 | 45 |
| Nov 20, 2026 | 7d | $1.38 | +35.29% | 38 | 1,517 |
| Nov 27, 2026 | 14d | $1.68 | +7.01% | 20 | 63 |
| Dec 4, 2026 | 21d | $1.43 | -35.87% | 5 | 15 |
| Dec 11, 2026 | 28d | $1.45 | +0.00% | 17 | 17 |
| Dec 18, 2026 | 35d | $1.90 | +1.06% | 410 | 610 |
| Dec 24, 2026 | 41d | — | — | 0 | 9 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $2.00 | +8.11% | 356 | 54,211 |
| Mar 19, 2027 | 126d | $1.84 | -10.68% | 20 | 142 |
| Apr 16, 2027 | 154d | $1.65 | +1.23% | 10 | 37 |
| May 21, 2027 | 189d | $2.70 | +14.89% | 60 | 40 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.